Overview

Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma

Status:
Terminated
Trial end date:
2017-10-31
Target enrollment:
0
Participant gender:
All
Summary
This randomized pilot phase II trial studies how well giving dalteparin, lenalidomide, and low-dose dexamethasone together works in treating patients with previously untreated multiple myeloma. Anticoagulants, such as dalteparin, may help prevent blood clots from forming in patients being treated with lenalidomide and dexamethasone for multiple myeloma. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving dalteparin, lenalidomide, and dexamethasone together may be an effective treatment for multiple myeloma
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Southern California
Collaborators:
Celgene Corporation
National Cancer Institute (NCI)
Treatments:
BB 1101
Dalteparin
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Heparin, Low-Molecular-Weight
Lenalidomide
Thalidomide
Tinzaparin
Criteria
Inclusion Criteria:

- Patients must have a diagnosis of active MM requiring treatment, as diagnosed by a
bone marrow biopsy within 8 weeks prior to study enrollment

- Patients must not have received any previous treatment for MM (localized radiation
therapy or single agent pulse steroid therapy for acute MM crises is permitted)

- Life expectancy of greater than 12 weeks

- Eastern Cooperative Oncology Group (ECOG) performance status < 2 (Karnofsky >= 50%)

- Total bilirubin < 1.5 x upper limit of normal (ULN)

- Transaminases (aspartate aminotransferase [AST]/alanine aminotransferase [ALT]) < 2.5
x ULN

- Alkaline phosphatase < 2.5 ULN

- Platelets >= 75,000 cells/mm3

- Hemoglobin >= 8.0 g/dL

- Absolute neutrophil count (ANC) > 1,000 cells/mm3 NOTE: Patients with platelet count <
75,000 or hemoglobin < 8.0 g/dl,or ANC <1,000 cell/mm3 secondary to extensive bone
marrow disease can be enrolled at Principal Investigator's (PI) discretion with
appropriate transfusion and/or cytokine support

- Creatinine =< 2.5 mg/dL (=< 200 mmol/L) or creatinine clearance > 30 ml/min (as
calculated by the Cockcroft-Gault formula)

- Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy
test with a sensitivity of at least 50 mIU/mL within 10-14 days and again within 24
hours prior to prescribing lenalidomide for Cycle 1 and must either commit to
continued abstinence from heterosexual intercourse or begin TWO acceptable methods of
birth control, one highly effective method and one additional effective method AT THE
SAME TIME, at least 28 days before she starts taking lenalidomide; FCBP must also
agree to ongoing pregnancy testing; men must agree to use a latex condom during sexual
contact with a FCBP even if they have had a successful vasectomy

- All study participants must be registered into the mandatory RevAssist program, and be
willing and able to comply with the requirements of RevAssist

- Willingness and ability to sign informed consent for the clinical trial

Exclusion Criteria:

- Patients who have had any prior chemotherapy for MM; with the exception of pulse
steroids for any myeloma-related acute events

- Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy
considered investigational

- Pregnant or lactating women

- Active serious infections uncontrolled by antibiotics at the time of treatment
initiation

- Inability to give voluntary written informed consent before performance of any
study-related procedure not part of normal medical care, with the understanding that
consent may be withdrawn by the subject at any time without prejudice to future
medical care

- Failure to comply with birth control methods as described above

- Any serious medical or psychiatric condition or reason that, in the PI's opinion,
makes the patient unsuitable to participate in this clinical trial

- Known to be human immunodeficiency virus (HIV) positive (if the status of HIV is not
known and patient is not at risk, as determined by the PI, then the patient will not
be specifically tested for HIV); HIV-positive patients on combination antiretroviral
therapy are ineligible because of the potential for pharmacokinetic interactions with
lenalidomide and/or dalteparin. In addition, these patients are at increased risk of
lethal infections when treated with marrow-suppressive therapy

- Diagnosed or treated for another malignancy within 3 years of enrollment, with the
exception of complete resection of basal cell carcinoma or squamous cell carcinoma of
the skin, an in situ malignancy, or low-risk prostate cancer (organ-confined, early
stage disease) after curative therapy

- Patients with M protein >6 gm/dl prior to starting treatment will be excluded from the
initial "run-in" cohort on both arms of the study, but will be eligible for the
subsequent enrollment of patients who do not have a run-in phase with dalteparin